Helen Q. Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Helen Q. Huang has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Lari Wenzel
University of California, Irvine, Irvine, CA
5 shared publications - Joan L. Walker
Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City, OK
4 shared publications - David Cella
Northwestern University, Evanston, USA
2 shared publications - David S. Alberts
Department of Medicine, University of Arizona College of Medicine, 1501 N. Campbell Avenue, Tucson, AZ 85724, USA
2 shared publications - Jason A. LaChance
Maine Medical Partners Women’s Health Division of Gynecologic Oncology, Scarborough, ME 04074, United States of America
2 shared publications - Matthew P. Boente
U.S. Medical Affairs, Gyn-Oncology, Genentech, South San Francisco, CA 94080, United States of America
2 shared publications
Latest Publications
- 20 September 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 163 (2) , 392-397
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study
- 20 September 2021
- Published by Elsevier in Gynecologic Oncology
- Vol. 163 (2) , 392-397
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study
- 1 January 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 156 (1) , 131-139
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study
- 1 January 2020
- Published by Elsevier in Gynecologic Oncology
- Vol. 156 (1) , 131-139
Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study
- 1 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 155 (3) , 452-460
GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE)
- 1 December 2019
- Published by Elsevier in Gynecologic Oncology
- Vol. 155 (3) , 452-460
GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE)
- 1 July 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 150 (1) , 119-126
Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
- 1 July 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 150 (1) , 119-126
Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study
- Open Access
- 1 February 2015
- Published by Elsevier in Gynecologic Oncology
- Vol. 136 (2) , 323-327
Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: Characteristics associated with toxicity and the effect of substitution with docetaxel: An NRG Oncology/Gynecologic Oncology Group study
- 1 February 2015
- Published by Elsevier in Gynecologic Oncology
- Vol. 136 (2) , 323-327
Open AccessNeurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: Characteristics associated with toxicity and the effect of substitution with docetaxel: An NRG Oncology/Gynecologic Oncology Group study
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 5075
The association between quality of life and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group study.
5075 Background: To explore the association between baseline quality-of-life (QOL) domain scores and overall survival (OS) in ovarian cancer patients receiving adjuvant chemotherapy. Methods: Patients with optimal stage III ovarian cancer on Gynecologic Oncology Group protocol #172 completed the Functional Assessment of Cancer Therapy-Generic (FACT-G) and were then randomly assigned to either intravenous (IV) or intraperitoneal (IP) chemotherapy. The FACT scale includes physical, functional, social, and emotional well- being domains (PWB, FWB, SWB, EWB). Patients who rated their lack of energy as ‘"quite a bit" or "very much" were compared with those who reported higher energy levels. Results: After adjusting for patient age, treatment assignment, and the presence of gross disease, only the PWB subscale was significantly associated with OS. Patients who reported baseline PWB scores in the lowest quantile (PWB score < 15 points) had decreased OS (HR: 1.81; 95% CI: 1.2∼f2.72; p = 0.005) relative to those who scored within the highest quantile (PWB score > 24 points). For every mean item point decrease in PWB, patients were at a 20% increased risk of death (hazard ratio [HR]: 0.80; 95% CI: 0.68 ∼f 0.93; p = 0.005). Patients with lower reported energy levels did not have an increased risk of death compared with those with higher reported energy levels (HR: 1.21; 95% CI: 0.91∼f1.61; p = 0.19). Conclusions: Poor PWB reported at baseline is associated with increased risk of death in patients undergoing adjuvant chemotherapy for advanced ovarian cancer. Identification of factors that result in these low scores may lead to targeted support to improve outcomes in this group of women. No significant financial relationships to disclose.
- 20 May 2010
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 5075
The association between quality of life and overall survival in ovarian cancer patients during adjuvant chemotherapy: A Gynecologic Oncology Group study.
5075 Background: To explore the association between baseline quality-of-life (QOL) domain scores and overall survival (OS) in ovarian cancer patients receiving adjuvant chemotherapy. Methods: Patients with optimal stage III ovarian cancer on Gynecologic Oncology Group protocol #172 completed the Functional Assessment of Cancer Therapy-Generic (FACT-G) and were then randomly assigned to either intravenous (IV) or intraperitoneal (IP) chemotherapy. The FACT scale includes physical, functional, social, and emotional well- being domains (PWB, FWB, SWB, EWB). Patients who rated their lack of energy as ‘"quite a bit" or "very much" were compared with those who reported higher energy levels. Results: After adjusting for patient age, treatment assignment, and the presence of gross disease, only the PWB subscale was significantly associated with OS. Patients who reported baseline PWB scores in the lowest quantile (PWB score < 15 points) had decreased OS (HR: 1.81; 95% CI: 1.2∼f2.72; p = 0.005) relative to those who scored within the highest quantile (PWB score > 24 points). For every mean item point decrease in PWB, patients were at a 20% increased risk of death (hazard ratio [HR]: 0.80; 95% CI: 0.68 ∼f 0.93; p = 0.005). Patients with lower reported energy levels did not have an increased risk of death compared with those with higher reported energy levels (HR: 1.21; 95% CI: 0.91∼f1.61; p = 0.19). Conclusions: Poor PWB reported at baseline is associated with increased risk of death in patients undergoing adjuvant chemotherapy for advanced ovarian cancer. Identification of factors that result in these low scores may lead to targeted support to improve outcomes in this group of women. No significant financial relationships to disclose.
- 1 February 2007
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 17 (2) , 387-393
Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study
- 1 February 2007
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 17 (2) , 387-393
Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study